Beam Therapeutics Outlines Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provides Preclinical Data Updates at ASH
CAMBRIDGE, Mass., Dec. 12, 2021 -- Beam Therapeutics Inc. , a biotechnology company developing precision genetic medicines through base editing, today shared a three-stage, long-term... | December 12, 2021
Source: marketscreener.com